AVTXAvalo Therapeutics Inc. Common Stock
19.83USD-4.43%Mkt Cap: 1.06B $P/E: —3d ago
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy? Avalo Therapeutics, Inc. reported past earnings for the second quarter and first half of 2026, with net losses of US$36.36 million and US$55.99 million respectively, both higher than the same periods a year earlier. Despite the larger overall losses, the basic and diluted loss per share from continuing operations improved year-on-year for both the quarter and the six-month period, hinting at progress in managing shareholder dilution or capital structure. With this backdrop of higher net... | ||
IInsider Monkey | ||
MMT Newswires | ||